Clinical Effect of Liuwei Anshen Capsule Combined with Aripiprazole in the Treatment of Schizophrenia
Objective To explore the efficacy and safety of using Liuwei Anshen Capsules in addition to aripiprazole in the treatment of schizophrenia.Methods 102 cases of schizophrenia patients admitted to Ankang Central Hospital from January 2021 to April 2024 were selected and divided into the control group and the combined group according to the random number table method,each with 51 cases.The control group was treated with aripiprazole;the combined group was treated with Liuwei Anshen Capsules on the basis of aripiprazole.After 4 weeks of treatment,the clinical efficacy of the two groups was evaluated and compared.Positive and negative syndrome scale ( PANSS ) scores and the comprehensive quality of life questionn aire-74 ( GQOLI-74 ) scores were evaluated and compared between two groups before and after treatment.The levels of serum nerve injury markers were detected and compared between two groups before and after treatment.The incidence of adverse drug reactions during the treatment process was recorded.Results The total effective rate of the combined group after 4 weeks of treatment was higher than that of the control group ( P<0.05 ) .After 4 weeks of treatment,the PANSS score,serum S100β protein,neuron-specific enolase,and myelin basic protein in the combined group were lower than those in the control group,while the GQOLI-74 score was higher than that of the control group ( P<0.05 ) .There was no significant difference in the incidence of adverse reactions between the two groups during the treatment process ( P>0.05 ) .Conclusion The addition of Liuwei Anshen Capsules to aripiprazole in the treatment of schizophrenia had a better effect,could better improve clinical symptoms,and was safe.
SchizophreniaLiuwei Anshen CapsuleAripiprazoleNeuron-Specific EnolaseMyelin Basic ProteinComparative Study of Therapeutic EffectsSafety
万方数据
维普
